Crossmark

Incidence of herpes zoster in transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone

Crossref DOI link: https://doi.org/10.1007/s12185-025-03980-8

Published Online: 2025-03-31

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Horigome, Yuichi

Kamata, Hirotoshi

Michishita, Yusuke

Yokoyama, Maki

Tadera, Noriyuki

Hayama, Kei

Suzuki, Takahiro https://orcid.org/0000-0002-8438-2186
License Information

Text and Data Mining valid from 2025-03-31

Version of Record valid from 2025-03-31
More Information

Article History

Received: 19 November 2024

Revised: 20 March 2025

Accepted: 24 March 2025

First Online: 31 March 2025

Declarations

:

: YH received honoraria from Janssen Pharmaceutical K.K., Bristol-Myers Squibb, and Sanofi. HK received honoraria from Janssen Pharmaceutical K.K., Bristol-Myers Squibb, and Sanofi. NT received honoraria from Sanofi. KH received honoraria from Bristol-Myers Squibb. TS received honoraria from Janssen Pharmaceutical K.K., Bristol-Myers Squibb, and Sanofi. The other authors declare no competing financial interests.

Document is current

Any future updates will be listed below